|
|||||
|
|
Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections |
|
| Authors: | Shivani B. Kaushik Mark G. Lebwohl |
| Affiliation: | Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York |
| Abstract: | |
| Keywords: | acitretin adalimumab apremilast biologic brodalumab certolizumab cyclosporine comorbidities etanercept golimumab hepatitis HIV IL-12/23 IL-17 IL-23 infliximab ixekizumab psoriasis psoriatic arthritis methotrexate pediatric pregnancy secukinumab systemic TNF-α traditional agents tuberculosis ustekinumab FDA Food and Drug Administration HBV hepatitis B virus HCV hepatitis C virus LFT liver function test LTBI latent tuberculosis infection PASI Psoriasis Area and Severity Index TNF tumor necrosis factor VACTERL vertebral anomalies, anal atresia cardiac defects, tracheoesophageal fistula and/or esophageal atresia, renal and radial anomalies and limb defects |
| 本文献已被 ScienceDirect 等数据库收录！ | |